Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 755 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Motility Disorder Clear all
Completed No phase listed Observational

A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma

NCT06381583
View directory record Official record
Conditions
Esophagus Cancer, Esophageal Cancer Stage, Esophageal Cancer, Esophageal Neoplasms, Esophagus Adenocarcinoma, Esophagus, Barrett, Barrett Esophagus, Barrett Adenocarcinoma, Barrett Epithelium, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia, Barretts Esophagus With High Grade Dysplasia, Barretts Esophagus With Low Grade Dysplasia, Barrett Esophagus, Long-Segment, Barrett's Esophagus With Dysplasia, Unspecified, Barrett's Esophagus With Esophagitis, Gastroesophageal Reflux, Reflux Disease, Esophageal Adenocarcinoma, Esophageal Dysplasia, Esophageal Neoplasms Malignant
Interventions
EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia)
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
658 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 24, 2026, 10:57 PM EDT
Terminated Not applicable Interventional

Registry Study of the NDO Surgical Plicator for the Treatment of GERD

NCT00597792
View directory record Official record
Conditions
GERD
Interventions
NDO Full-thickness Plicator
Device
Lead sponsor
NDO Surgical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
7
States / cities
Macon, Georgia • Evanston, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 30, 2008 · Synced Oct 24, 2026, 10:57 PM EDT
Completed Phase 4 Interventional Results available

Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study

NCT00693225
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Omeprazole/sodium bicarbonate
Drug
Lead sponsor
Yvonne Romero
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 20, 2012 · Synced Oct 24, 2026, 10:57 PM EDT
Completed Phase 1 Interventional

A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive

NCT00747526
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
1 Month to 11 Months
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
13
States / cities
Little Rock, Arkansas • Oakland, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Oct 24, 2026, 10:57 PM EDT
Completed Phase 2 Interventional Results available

A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience

NCT01043185
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
AZD3355, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 14, 2011 · Synced Oct 24, 2026, 10:57 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

NCT01280344
View directory record Official record
Conditions
Gastrointestinal Dysmotility
Interventions
Saline Solution for Injection, Ipamorelin
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
45
States / cities
Florence, Alabama • Sheffield, Alabama • Fountain Valley, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 24, 2026, 10:57 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease

NCT05890001
View directory record Official record
Conditions
Non-erosive Reflux Disease, Erosive Esophagitis
Interventions
BLI5100
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
60
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 24, 2026, 10:57 PM EDT
Terminated Not applicable Interventional Results available

Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study

NCT01327963
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Transoral Incisionless Fundoplication
Device
Lead sponsor
EndoGastric Solutions
Industry
Eligibility
18 Years to 85 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Ocala, Florida • Salem, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 24, 2026, 10:57 PM EDT
Completed Phase 3 Interventional

Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

NCT00241514
View directory record Official record
Conditions
GERD
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
19
States / cities
Tucson, Arizona • Anaheim, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2011 · Synced Oct 24, 2026, 10:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease

NCT03619811
View directory record Official record
Conditions
Gastroesophageal Reflux, Laryngopharyngeal Reflux
Interventions
Reflux Band® Upper Esophageal Sphincter (UES) Assist Device
Diagnostic Test
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 89 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 24, 2026, 10:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]APN-1607 as a PET Biomarker

NCT05005819
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Healthy Volunteers
Interventions
[18F] APN-1607
Drug
Lead sponsor
Invicro
Other
Eligibility
50 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 24, 2026, 10:57 PM EDT
Completed No phase listed Observational

Esophageal Motility in Reflux Induced Cough

NCT02492126
View directory record Official record
Conditions
Cough
Interventions
Citric Acid
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 24, 2026, 10:57 PM EDT
Completed Not applicable Interventional Results available

Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing

NCT02930824
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
CYP2C19 genotyping
Genetic
Lead sponsor
University of Florida
Other
Eligibility
5 Years to 100 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Gainesville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 24, 2026, 10:57 PM EDT
Completed Not applicable Interventional Results available

LINX Reflux Management System Clinical Study Protocol

NCT00776997
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Magnetic Sphincter Augmentation
Device
Lead sponsor
Torax Medical Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 24, 2026, 10:57 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

NCT06687603
View directory record Official record
Conditions
Barrett Esophagus, Gastroesophageal Reflux, Esophageal Adenocarcinoma
Interventions
EsoCheck, EsoGuard
Device · Diagnostic Test
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
50 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
5
States / cities
Aurora, Colorado • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 24, 2026, 10:57 PM EDT
Completed Phase 2 Interventional Results available

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT01472939
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
SSP-002358 (0.1 mg) + PPI, SSP-002358 (0.5 mg) + PPI, SSP-002358 (2.0 mg) + PPI, Placebo + PPI
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
62
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 24, 2026, 10:57 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The CurePSP Genetics Program

NCT06647641
View directory record Official record
Conditions
PSP, PSP - Progressive Supranuclear Palsy, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration Syndrome, Corticobasal Degeneration, Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), MSA, MSA - Multiple System Atrophy, MSA-C, Multiple System Atrophy, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Multiple System Atrophy - Cerebellar Subtype (MSA-C), Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy, Cerebellar Type, Multiple System Atrophy, Parkinsonian Type, Progressive Supranuclear Palsy, Progressive Supranuclear Palsy(PSP), Progressive Supranuclear Palsy (PSP)
Interventions
Whole genome sequencing will be performed at the NIH
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
35 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 24, 2026, 10:57 PM EDT
Terminated No phase listed Observational

Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux

NCT00451841
View directory record Official record
Conditions
Cough, Gastroesophageal Reflux
Interventions
RTube Exhaled Breath Condensate Collection System
Device
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 24, 2026, 10:57 PM EDT
Withdrawn Not applicable Interventional

Proton Pump Inhibitor Therapy for Mild to Moderate Obstructive Sleep Apnea

NCT00211614
View directory record Official record
Conditions
Obstructive Sleep Apnea, Gastroesophageal Reflux
Interventions
Lansoprazole
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Oct 24, 2026, 10:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Esophageal Motility and Airway Defenses Among Infants

NCT00062452
View directory record Official record
Conditions
Infant, Premature, Diseases, Congenital Abnormalities, Perinatal Asphyxia
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Weeks to 6 Months
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 24, 2026, 10:57 PM EDT
Completed No phase listed Observational

Diagnosis and Natural History Study of Patients With Neurological Conditions

NCT00001549
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Movement Disorder, Multiple System Atrophy, Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 10:57 PM EDT
Completed No phase listed Observational

Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine

NCT05012358
View directory record Official record
Conditions
Mitochondrial Myopathies, Mitochondrial DNA Mutation, Mitochondrial Diseases, Chronic Progressive External Ophthalmoplegia With Myopathy, Kearns-Sayre Syndrome
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
15 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 24, 2026, 10:57 PM EDT
Terminated Phase 2 Interventional Results available

Study of BIIB092 in Participants With Progressive Supranuclear Palsy

NCT03068468
View directory record Official record
Conditions
Supranuclear Palsy, Progressive
Interventions
BIIB092, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
41 Years to 86 Years
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 24, 2026, 10:57 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

NCT06355531
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
FNP-223, Placebo
Drug
Lead sponsor
Ferrer Internacional S.A.
Industry
Eligibility
50 Years to 80 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Carlsbad, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 24, 2026, 10:57 PM EDT